Zantac Lawsuit Lawyer
Zantac Class-Action Lawsuit Over Recalled Antacid
A Zantac class-action lawsuit has been filed in relation to injuries caused by the antacid drug used to prevent heartburn and acid indigestion. A second class-action lawsuit against Zantac was also filed alleging that various manufacturers, sellers, and distributors were aware of and failed to disclose to the public the presence of dangerously high levels of a known probable carcinogen N-nitrosodimethylamine (NDMA) forming during the storage and consumption of Zantac. If you or a loved one has developed cancer following three-months continuous use of Zantac, you should consult a Zantac class-action lawsuit lawyer immediately. You may be entitled to legal compensation for your damages.
Why Was Zantac Recalled?
On April 1, 2020, The FDA announced that they were sending letters to all manufacturers of Zantac requesting that they withdraw Zantac from the market entirely and advising consumers to stop taking the drug immediately as a result of the discovery that Zantac not only contains a known carcinogen, N-nitrosodimethylamine (NDMA) but also that the levels of NDMA in Zantac increase over time with normal storage of the product. NDMA is a known carcinogen–a substance that can cause cancer when you are exposed to certain levels. The FDA noted that NDMA levels increase as Zantac is stored under typical storage conditions but that it goes up even more when stored under hotter conditions such as in warehouses or non-air-conditioned rooms.
History of the Investigation into Zantac
On September 9th, 2019, a company called Valisure petitioned the FDA to order a voluntary recall of Zantac. Valisure is an online pharmacy that boasts analyzing each batch of medicine before it distributes to consumers. They are effectively the whistleblower in this class action. Their tests suggested that Ranitidine can react with itself under certain conditions resulting in the production of NDMA at levels extremely higher than the FDA allowable daily intake limit of 96 nanograms. “Valisure has detected NDMA in excess of 3,000,000 nanograms per tablet…likely due to an inherent instability in the ranitidine molecule,” according to their petition.
On October 2, 2019, the FDA reported finding “unacceptable levels” of NDMA in some samples tested. Since the FDA’s finding, a number of manufacturers including GlaxoSmithKline and Sanofi have instituted voluntary recalls while the FDA investigates Valisure’s findings. Upon this discovery, many retailers of the product began pulling it from the shelves at that time. The FDA’s ongoing investigation has now determined that the NDMA levels rise over time as the product is stored, particularly if stored in higher temperatures.
What is Zantac?
Zantac is the brand name for the antacid drug Ranitidine Hydrochloride. It is commonly used to treat heartburn, indigestion, peptic ulcers, acid-reflux disease a/k/a/ GERD, Zollinger-Ellison syndrome, and to prevent ulcers. Zantac has been available since the 1980s. It may be obtained by prescription or purchased over-the-counter.
What is N-Nitrosodimethylamine?
N-Nitrosodimethylamine (NDMA) is a byproduct of many industrial manufacturing processes, including the manufacturing of unsymmetrical dimethylhydrazine, which is a component of rocket fuel that requires NDMA for its synthesis. It is classified as a B2 carcinogen–meaning it is known to cause cancer in animals and a probable cause of cancer in humans. This is the same agent that is fueling the Valsartan lawsuits. Trace amounts can be found in some foods but are generally not believed to be harmful. The FDA will allow trace amounts up to 96 nanograms in drugs meant for human consumption.
Does Zantac Contain NDMA?
There is a certain trace amount of NDMA expected to be found in Zantac as in many drugs. However, the NDMA levels are problematic in Zantac for two reasons: First, the NDMA levels tend to increase over time as the product is stored. Second, Valisure’s tests suggest the NDMA levels elevate when Zantac hits the stomach fluid containing nitrate—a compound formed from nitrogen and oxygen. Nitrate is found in certain foods, particularly processed meats. These two problems for the basis of the Zantac class-action lawsuits.
Zantac Class Action Lawsuit Details
The first Zantac class-action lawsuit was filed in California on September 13, 2019, against Sanofi-Aventis, U.S. LLC, Sanofi US Services, Inc., Chattem, Inc. (drug distributor), and Boehringer Ingelheim Pharmaceuticals, Inc. The second Zantac class-action lawsuit was filed in New York on October 15, 2019. The latter additionally named retailers of the drug: CVS Health Co and Dollar Tree Stores, Inc.
What Types of Cancer are Linked to Zantac?
The link between Zantac (ranitidine) and elevated NDMA resulting in the potential to cause cancer is still under investigation. Types of cancer under investigation include:
- Bladder cancer
- Colorectal cancer
- Esophageal cancer
- Intestinal cancer
- Kidney cancer
- Liver cancer
- Ovarian cancer
- Pancreatic cancer
- Stomach cancer
- Testicular cancer
- Uterine cancer
Talk to a Lawyer for Zantac Cancer Claims
If you have developed cancer as after three months or more of taking Zantac or its generic equivalents, you may have a case. We are currently interested in evaluating cases involving:
- Three months or longer regular use prior to the diagnosis of one of the listed cancers, and;
- Took brand name Zantac in any state except Michigan, OR
- Took generic Zantac in California, Illinois, Massachusetts, or Vermont.
Other attorneys may set different criteria. If you believe you may qualify for the Zantac class-action lawsuit under the above criteria, call Simmons and Fletcher, P.C. to get connected with a Zantac lawsuit lawyer today.